ImmunoGenesis Showcases STING Agonist Progress at SITC
STING Agonists: The Next Frontier in Glioblastoma Treatment? Out there in the weeds of immunotherapy, ImmunoGenesis is gearing up for its moment at the SITC 2026 Annual Meeting with its STING agonist, IMGS-203. The stakes are skyscraper-high as this novel treatment makes a play against recurrent glioblastoma (GBM)—one tough cookie in the realm of brain cancers....
Continue Reading